Ganetespib radiosensitization for liver cancer therapy

References

• Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg 2012 2014; 3:71-6; PMID: 25568791; http://dx.doi.org/10.1016/j.amsu.2014.06.006
   Google Scholar
• Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47:131-6; PMID:10861275; http://dx.doi.org/10.1136/gut.47.1.131
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:70514; PMID: 16702586; http://dx.doi.org/10.7326/0003-4819-144-10-200605160-00004
   Google Scholar
• Annemarie W, Scott G, Kathleen G. Centers for disease ontrol and prevention. Surveillance for Acute Viral Hepatitis — United States, 2006. Wasington, D.C.: 2008.
   Google Scholar
• Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol Off J Am Soc Clin Oncol 2009; 27:1485-91; PMID: 19224838; http://dx.doi.org/10.1200/JCO.2008.20.7753
   PubMed Web of Science ®Google Scholar
• Hosemann S. Compass: hepatocellular carcinoma. OncoLog 2013; 58:1.
   Google Scholar
• Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 2013; 87:22-32; PMID:23219567; http://dx.doi.org/10.1016/j.ijrobp.2012.08.043
   PubMed Web of Science ®Google Scholar
• Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, et al. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs 2015 Feb;33(1):128-37; PMID:25248753; http://dx.doi.org/10.1007/s10637-014-0164-8
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58; PMID:11902585; http://dx.doi.org/10.1038/nrc706
   PubMed Web of Science ®Google Scholar
• Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136:823-37; PMID:19269363; http://dx.doi.org/10.1016/j.cell.2009.02.024
   PubMed Web of Science ®Google Scholar
• Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, et al. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther 2013; 14:347-56; PMID:23358469; http://dx.doi.org/10.4161/cbt.23626
   PubMed Web of Science ®Google Scholar
• Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012; 11:475-84; PMID:22144665; http://dx.doi.org/10.1158/1535-7163.MCT-11-0755
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer 2014; 14:154-60; PMID:24512858; http://dx.doi.org/10.1016/j.clbc.2013.12.012
   PubMed Web of Science ®Google Scholar
• Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2013; 19:3068-77; PMID: 23553849; http://dx.doi.org/10.1158/1078-0432.CCR-12-3381
   PubMed Web of Science ®Google Scholar
• Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44:694-8; PMID:22561517; http://dx.doi.org/10.1038/ng.2256
   PubMed Web of Science ®Google Scholar
• Wang Y-W, Lin K-T, Chen S-C, Gu D-L, Chen C-F, Tu P-H, Jou Y-S. Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma. Hepatol Baltim Md 2013; 58:239-50; PMID: 23460382; http://dx.doi.org/10.1002/hep.26352
   PubMed Web of Science ®Google Scholar
• Wang C, Jin G, Jin H, Wang N, Luo Q, Zhang Y, Gao D, Jiang K, Gu D, Shen Q, et al. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma. Oncotarget 2015 Feb 20;6(5):2903-16; PMID: 25609201; http://dx.doi.org/10.18632/oncotarget.3093; 29
   Web of Science ®Google Scholar
• Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27:55-76; PMID:17295177; http://dx.doi.org/10.1055/s-2006-960171
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25:3778-86; PMID:16799619; http://dx.doi.org/10.1038/sj.onc.1209547
   PubMed Web of Science ®Google Scholar
• Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007; 26:3227-39; PMID:17496918; http://dx.doi.org/10.1038/sj.onc.1210414
   PubMed Web of Science ®Google Scholar
• Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992; 258:478-80; PMID:1411546; http://dx.doi.org/10.1126/science.1411546
   PubMed Web of Science ®Google Scholar
• Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009; 25:186-94; PMID: 19387255; http://dx.doi.org/10.1097/MOG.0b013e32832962a1
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, Santoro A, Raoul J-L, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34; PMID:19095497; http://dx.doi.org/10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci 2012; 57:1122-9; PMID:22451120; http://dx.doi.org/10.1007/s10620-012-2136-1
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 2013; 14:e358-69; PMID:23896275; http://dx.doi.org/10.1016/S1470-2045(13)70169-4
   PubMed Web of Science ®Google Scholar
• Lamoureux F, Thomas C, Yin M-J, Fazli L, Zoubeidi A, Gleave ME. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Eur Urol 2014; 66:145-55; PMID:24411988; http://dx.doi.org/10.1016/j.eururo.2013.12.019
   PubMed Web of Science ®Google Scholar
• Wang Y, Trepel JB, Neckers LM, Giaccone G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs Lond Engl 2000 2010; 11:1466-76
   PubMedGoogle Scholar
• Proia DA, Blackman RK, Foley KP, He S, Kepros J, Korbut T, Sang J, Smith D, Ying W, Zhang C, et al. The next generation Hsp90 inhibitor STA-9090, currently in phase 2 trials, displays potent in vitro and in vivo activity. Ann Oncol 2010; 21:ii35; PMID:22806877; http://dx.doi.org/10.1158/1078-0432.CCR-11-2967
   Web of Science ®Google Scholar
• Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PloS One 2011; 6:e18552; PMID:21533169; http://dx.doi.org/10.1371/journal.pone.0018552
   PubMed Web of Science ®Google Scholar
• Gomez-Casal R, Bhattacharya C, Epperly MW, Basse PH, Wang H, Wang X, Proia DA, Greenberger JS, Socinski MA, Levina V. The HSP90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells. Cancers 2015; 7:876-907; PMID:26010604; http://dx.doi.org/10.3390/cancers7020814
   PubMed Web of Science ®Google Scholar
• Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan L, Lian C, Shi H, Chen K, Tu Z. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis 2015; 6:e1595; PMID:25590805; http://dx.doi.org/10.1038/cddis.2014.555
   PubMedGoogle Scholar
• Patel K, Wen J, Magliocca K, Muller S, Liu Y, Chen ZG, Saba N, Diaz R. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Cancer Chemother Pharmacol 2014; 74:1015-22; PMID:25205430; http://dx.doi.org/10.1007/s00280-014-2584-8
   PubMed Web of Science ®Google Scholar
• Machida H, Matsumoto Y, Shirai M, Kubota N. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 2003; 79:973-80; PMID:14713575; http://dx.doi.org/10.1080/09553000310001626135
   PubMed Web of Science ®Google Scholar
• Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003; 63:8984-95; PMID:14695217
   PubMed Web of Science ®Google Scholar
• Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res Off J Am Assoc Cancer Res 2003; 9:3749-55; PMID: 14506167
   PubMed Web of Science ®Google Scholar
• Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 2008; 7:1985-92; PMID:18645008; http://dx.doi.org/10.1158/1535-7163.MCT-07-2104
   PubMed Web of Science ®Google Scholar
• He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs 2014; 32:577-86; PMID:24682747; http://dx.doi.org/10.1007/s10637-014-0095-4
   PubMed Web of Science ®Google Scholar
• Wild AT, Gandhi N, Chettiar ST, Aziz K, Gajula RP, Williams RD, Kumar R, Taparra K, Zeng J, Cades JA, et al. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. PloS One 2013; 8:e65726; PMID:23762417; http://dx.doi.org/10.1371/journal.pone.0065726
   PubMedGoogle Scholar
• Wong J, Armour E, Kazanzides P, Iordachita I, Tryggestad E, Deng H, Matinfar M, Kennedy C, Liu Z, Chan T, et al. High-Resolution, small animal radiation research platform with X-ray tomographic guidance capabilities. Int J Radiat Oncol 2008; 71:1591-9;PMID: 18640502; http://dx.doi.org/10.1016/j.ijrobp.2008.04.025
   PubMed Web of Science ®Google Scholar
• Tran PT, Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J, Horng G, Hughes NP, Schwartz LH, Miller VA, et al. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med 2011; 3:103ra99; PMID:21974937; http://dx.doi.org/10.1126/scitranslmed.3002018
   PubMed Web of Science ®Google Scholar
• Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 1984; 99:73-84; PMID:6739728; http://dx.doi.org/10.2307/3576448
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2008; 14:5142-9; PMID: 18698032; http://dx.doi.org/10.1158/1078-0432.CCR-07-4072
   PubMed Web of Science ®Google Scholar